PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

🧠 Clinical library

Clinical Specialty Index

623 articles indexed across 24 specialties, each reviewed by a licensed pharmacist before publication.

Showing 90 from 1 topic.Sort: Newest | Oldest
Ivonescimab Beats Tislelizumab on Survival in Squamous Lung Cancer
Analysis Oncology Pharmacy Practice-changing Grade: High

Ivonescimab enhances survival in squamous NSCLC, offering new hope.

Variant-Stratified ALK Inhibitor Selection in EML4-ALK Lung Cancer
Analysis Oncology Pharmacy Confirmatory Grade: Low

EML4-ALK fusion: A precision target in NSCLC fraught with resistance challenges.

ECIL-10 Reshapes Febrile Neutropenia Antibiotic Strategy Around Stewardship
★ Editor's Pick Guideline Infectious Disease / Antimicrobials Practice-changing Grade: Moderate
Also in Oncology

Rising resistance challenges febrile neutropenia treatment in hematologic patients.

Low-Dose Vitamin D3 With Fluoropyrimidines in Metastatic CRC: Small, Unregistered, Exploratory
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low

Vitamin D3 boosts chemotherapy response in metastatic CRC.

Sequencing Systemic Therapy in Resectable NSCLC: Equipoise Remains
Analysis Oncology Pharmacy Confirmatory Grade: Moderate

New trials may refine lung cancer therapy timing strategies.

KDIGO Consensus Reframes Kidney-Heart Failure Comanagement Priorities
Analysis Oncology Pharmacy Confirmatory Grade: Low
Also in Nephrology

Preventing kidney damage in cancer treatment requires proactive strategies.

Pooled 5-FU Population PK Model Supports Lean Mass and Model-Informed Dosing
Analysis Pharmacokinetics / TDM Hypothesis-generating Grade: Low
Also in Oncology

Leverage lean body mass for precise 5-FU dosing!

Venetoclax-Based Regimens Reshape Chemotherapy-Free CLL Management
Analysis Oncology Pharmacy Confirmatory Grade: Very Low

Venetoclax brings new promise to chronic lymphocytic leukemia management.

Daraxonrasib Shows Early Activity in RAS-Mutated Pancreatic Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low

Daraxonrasib shows promise in advanced RAS-mutated pancreatic cancer.

KRAS Inhibitors May Unlock Immunotherapy in Pancreatic Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low

KRAS inhibitors may revolutionize immunotherapy for pancreatic cancer.

Atezolizumab Plus FOLFOX Halves Recurrence in dMMR Stage III Colon Cancer
★ Editor's Pick Analysis Oncology Pharmacy Practice-changing Grade: High

Atezolizumab enhances survival in dMMR colon cancer.

Biomarker Strategies for Chemotherapy Cardiotoxicity: Promise Versus Validation
Analysis Oncology Pharmacy Confirmatory Grade: Very Low
Also in Cardiology

New biomarkers offer promise for early detection of chemotherapy-induced heart damage.

KRAS Inhibitors Reshape the Treatment Landscape in Pancreatic Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low

KRAS: From 'undruggable' to potential target in pancreatic cancer.

Adagrasib Shows Tumor-Agnostic Activity in Rare KRAS G12C Solid Tumors
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low

Adagrasib shows promise in rare KRASG12C-mutated tumors.

Sotorasib Shows Modest Activity in KRAS G12C Pancreatic Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low

Sotorasib offers hope for KRAS p.G12C-mutated pancreatic cancer.